Mucosis B.V. and PATH sign agreement to pursue Mimopath™-based oral diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company’s Mimopath™ technology in oral vaccines to prevent and treat severe diarrhea.

Severe dehydrating diarrhea is the second leading cause of death in children in developing countries and frequently causes disease in travelers visiting those areas. Shigella and enterotoxigenic E. coli (ETEC) are the leading bacterial causes of diarrhea. Currently, no vaccines against those bacteria exist. PATH supports the development of Shigella and ETEC vaccines.

Because Mimopath™-based vaccines have the potential to raise a strong immune response in the gut after oral administration, PATH is supporting Mucosis to establish proof of concept in animals. PATH will cover the company’s research costs up to US$600,000. If proof of concept is generated, the collaboration may be expanded.

“We are very proud to collaborate with PATH in applying our technology to the vital task of finding new vaccines targeting the threat of Shigella and ETEC,” said Govert Schouten, CEO of Mucosis.

Mucosis already collaborates with PATH on intranasal pneumococcal vaccines based on Mimopath™. This program started in 2009.

Leave a comment

Your email address will not be published. Required fields are marked *